



Post'd PCT/PTO 10 DEC 2004



INVESTOR IN PEOPLE

Best Available Copy

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 07 JUL 2003
WIPO PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated- 20 June 2003

THE PATENT OFFICE

G

13 JUN 2002

NEWPORT

The Patent Office

2002 E72544-2 DA/74
P01/00 000-0213580.4**Request for grant of a patent***(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form.)*

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

100692

2. Patent application number

(The Patent Office will fill in this part)

0213580.4

13 JUN 2002

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*AstraZeneca AB
S-151 85 Sodertalje
SwedenPatents ADP number *(if you know it)*

7822448003

If the applicant is a corporate body, give the country/state of its incorporation

Sweden

4. Title of the invention

METHODS

5. Name of your agent *(if you have one)*

Allen F Giles

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*AstraZeneca UK Limited
Global Intellectual Property
Mereside, Alderley Park
Macclesfield
Cheshire SK10 4TGPatents ADP number *(if you know it)*

6918463003

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and *(if you know it)* the or each application numberCountry Priority application number
(if you know it) Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application Date of filing
*(day / month / year)*8. Is a statement of inventorship and of right to grant of a patent required in support of this request? *(Answer 'Yes' if:*

- any applicant named in part 3 is not an inventor, or
- there is an inventor who is not named as an applicant, or
- any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description	15
Claim(s)	2
Abstract	
Drawing(s)	1 + 14

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents
(please specify)

9 (Sequence Listing)

11. I/We request the grant of a patent on the basis of this application.

Signature *Lynda M Slack* Date
Authorised Signatory

12 Jun 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Lynda M Slack - 01625-516173

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

METHODS

This invention relates to polymorphisms in the human OATPF gene and corresponding novel allelic polypeptides encoded thereby. The invention also relates to methods and 5 materials for analysing allelic variation in the OATPF gene, and to the use of OATPF polymorphism in treatment of diseases with OATPF transportable drugs.

Membrane transporters are important for the absorption of oral medications across the gastrointestinal tract, uptake in to target tissues such as the liver or brain, and excretion into the bile and urine. Changes in the activities of transporters may therefore have a significant 10 effect on the bioavailability of clinically important drugs.

It has been reported in the literature that polymorphisms in proteins involved in drug transport can alter the function of the protein. For example, the multidrug-resistance (MDR-1) gene contains a polymorphism in exon 26 (C345T) which has been correlated with expression levels and function of MDR-1. Individuals homozygous for this polymorphisms have 15 significantly lower duodenal MDR-1 expression and high digoxin plasma levels, suggesting this polymorphism affects the absorption and tissue concentrations of substrates of MDR-1 (S Hoffmeyer *et al.* Proceedings National Academy Science (2000) 97, 3473-3478).

The human sodium independent organic anion transporting polypeptide (OATP) F gene is a member of the OATP supergene family involved in multifunctional transport of 20 organic anions (I. Tamai *et al.* Biochemical and Biophysical Research Communications 273, 251-260 (2000); M. Kusuhara & Y. Sugiyama Journal of Controlled Release 78 (2002) 43-54). There is an alternative nomenclature for this family as SLC21A (solute carriers) and OATPF relates to SLC21A14. A cDNA sequence encoding OATPF has been submitted to the EMBL 25 database under accession number AF260704. A cDNA sequence encoding for OATPF has also been submitted to the EMBL database under accession number AF205076, and has been accorded the alternative name for OATPF of OATPRP5.

OATPF has a 43% identity at the amino acid level with its gene family member human OATPC (SLC21A6). OATPC has been shown to be involved in the transport of drugs involved in lipid lowering e.g. statins (D. Nakai *et al.* J Pharmacol Exp Ther 2001 297: 861-867). 30 Statins have been referred to as a first-line therapy for patients with atherosclerotic vascular diseases (B. Hsiang *et al.* J. Biol Chem 274, 37161-37168 (1999)). Due to its sequence homology, it is likely that OATPF may transport similar substrates as OATPC. OATPF is also

homologous to a rat gene named BSAT1. BSAT1 is expressed at the blood-brain barrier in rats and human homologues of this gene may be important in transport of pharmaceutical agents into the brain.

DNA polymorphisms are variations in DNA sequence between one individual and 5 another. DNA polymorphisms may lead to variations in amino acid sequence and consequently to altered protein structure and functional activity. Polymorphisms may also affect mRNA synthesis, maturation, transportation and stability. Polymorphisms which do not result in amino acid changes (silent polymorphisms) or which do not alter any known consensus sequences may nevertheless have a biological effect, for example by altering 10 mRNA folding or stability.

Knowledge of polymorphisms may be used to help identify patients most suited to therapy with particular pharmaceutical agents (this is often termed "pharmacogenetics"). Pharmacogenetics can also be used in pharmaceutical research to assist the drug selection process. Polymorphisms are used in mapping the human genome and to elucidate the genetic 15 component of diseases. The reader is directed to the following references for background details on pharmacogenetics and other uses of polymorphism detection: Linder *et al.* (1997), Clinical Chemistry, 43, 254; Marshall (1997), Nature Biotechnology, 15, 1249; International Patent Application WO 97/40462, Spectra Biomedical; and Schafer *et al.* (1998), Nature Biotechnology, 16, 33.

20 Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. Thus there is a need for improved approaches to pharmaceutical agent design and therapy.

Point mutations in polypeptides will be referred to as follows: natural amino acid (using 1 or 3 letter nomenclature), position, new amino acid. For (a hypothetical) example 25 "D25K" or "Asp25Lys" means that at position 25 an aspartic acid (D) has been changed to lysine (K). Multiple mutations in one polypeptide will be shown between square brackets with individual mutations separated by commas.

The first 54bp of genomic DNA sequence immediately upstream of the OATPF protein coding sequence is set out as SEQ ID NO: 15, with the first nucleotide of the genomic 30 DNA sequence accorded position 1. The position of the polymorphism in the genomic DNA sequence is defined with reference to SEQ ID NO: 15 unless stated otherwise or apparent from the context.

A cDNA sequence encoding OATPF is set out as SEQ ID NO: 16, with the first nucleotide of the OATPF coding region accorded position 65. All positions of polymorphisms in the human OATPF gene transcribed into messenger RNA (and thence cDNA) herein refer to the positions in SEQ ID NO: 16 unless stated otherwise or apparent 5 from the context.

All positions herein of polymorphisms in the OATPF polypeptide are defined with reference to SEQ ID NO: 17 unless stated otherwise or apparent from the context.

The present invention is based on the discovery of four polymorphisms in the human OATPF gene and one polymorphism in the genomic DNA sequence immediately upstream of 10 the human OATPF gene. The polymorphisms of the present invention may have a functional effect on the protein and hence alter the transport of pharmaceutical agents.

According to one aspect of the present invention there is provided a method for the detection of a polymorphism in OATPF in a human, which method comprises determining the sequence of the human at any one of the following positions: position 11-16 of SEQ ID NO: 15 15; positions 86, 505, 1339, 1991 of SEQ ID NO: 16; position 8 of SEQ ID NO: 17.

The term "human" includes both a human having or suspected of having an OATPF mediated response to a drug and an asymptomatic human who may be tested for predisposition or susceptibility to such a response. At each position the human may be homozygous for an allele or the human may be a heterozygote.

20 The term "detection of a polymorphism" refers to determination of the genetic status of an individual at a polymorphic position (in which the individual may be homozygous or heterozygous at each position).

The term "OATPF mediated response" means any disease in which changing the level of an OATPF mediated response or changing the biological activity of OATPF would be of 25 therapeutic benefit.

The term "polymorphism" includes nucleotide substitution, nucleotide insertion and nucleotide deletion, which in the case of insertion and deletion includes insertion or deletion of one or more nucleotides at a position of a gene and variable numbers of a repeated DNA sequence.

30 In one embodiment of the invention preferably the polymorphism is further defined as: polymorphism at position 11-16 is presence of TAAAAAA and/or insertion of ACTTTGAAAG in lieu thereof;

- polymorphism at position 86 is presence of A and/or G;
- polymorphism at position 505 is presence of C and/or T;
- polymorphism at position 1339 is presence of A and/or G;
- polymorphism at position 1991 is presence of A and/or T; and
- 5 polymorphism at position 8 is presence of Asn and/or Asp.

The polymorphism at position 11-16 of SEQ ID NO: 15 is the result of a deletion-insertion event defined as deletion of bases 11-16 of SEQ ID NO: 15 and insertion of ACTTTGAAAG in lieu thereof. This results in an overall extra four bases and it will be appreciated by the skilled person that this will have an effect on the numbering of positions 10 downstream of this. For example, position 17 of SEQ ID NO: 15 becomes position 21 after the deletion-insertion event. It will also be appreciated by the skilled person that it may not be necessary to sequence the entire 11-16 bases or the insertion at this position to distinguish between the two alleles. For example, position 11 is either a T or an A when comparing the sequence of the two alleles.

15 In Figure 1, the polymorphism at position 11-16 is shown relative to the +1 ATG start site of the OATPF gene (position 65 as defined in SEQ ID NO: 16). Splicing of the genomic DNA sequence of Fig. 1 results in excision of the intronic region to produce a spliced 5' UTR (position 1-64 as defined in SEQ ID NO: 16) immediately upstream of the OATPF gene.

Preferred methods for detection of nucleic acid polymorphism are amplification 20 refractory mutation system and restriction fragment length polymorphism.

The test sample of nucleic acid is conveniently a sample of blood, bronchoalveolar lavage fluid, sputum, or other body fluid or tissue obtained from an individual. It will be appreciated that the test sample may equally be a nucleic acid sequence corresponding to the sequence in the test sample, that is to say that all or a part of the region in the sample nucleic 25 acid may firstly be amplified using any convenient technique e.g. PCR, before analysis of allelic variation.

It will be apparent to the person skilled in the art that there are a large number of analytical procedures which may be used to detect the presence or absence of variant nucleotides at one or more polymorphic positions of the invention. In general, the detection of 30 allelic variation requires a mutation discrimination technique, optionally an amplification reaction and optionally a signal generation system. Table 1 lists a number of mutation detection techniques, some based on the PCR. These may be used in combination with a

number of signal generation systems, a selection of which is listed in Table 2. Further amplification techniques are listed in Table 3. Many current methods for the detection of allelic variation are reviewed by Nollau *et al.*, Clin. Chem. 43, 1114-1120, 1997; and in standard textbooks, for example "Laboratory Protocols for Mutation Detection", Ed. by U. 5 Landegren, Oxford University Press, 1996 and "PCR", 2nd Edition by Newton & Graham, BIOS Scientific Publishers Limited, 1997.

Abbreviations:

ALEX™	Amplification refractory mutation system linear extension
APEX	Arrayed primer extension
ARMS™	Amplification refractory mutation system
b-DNA	Branched DNA
bp	base pair
CMC	Chemical mismatch cleavage
COPS	Competitive oligonucleotide priming system
DGGE	Denaturing gradient gel electrophoresis
DHPLC	Denaturing high performance liquid chromatography
FRET	Fluorescence resonance energy transfer
LCR	Ligase chain reaction
MASDA	Multiple allele specific diagnostic assay
NASBA	Nucleic acid sequence based amplification
OATP	Na ⁺ -independent organic anion transporting polypeptide
OLA	Oligonucleotide ligation assay
PCR	Polymerase chain reaction
PTT	Protein truncation test
RFLP	Restriction fragment length polymorphism
SDA	Strand displacement amplification
SNP	Single nucleotide polymorphism
SSCP	Single-strand conformation polymorphism analysis
SSR	Self sustained replication
TGGE	Temperature gradient gel electrophoresis
UTR	Untranslated region

10

Table 1 - Mutation Detection Techniques

General: DNA sequencing, Sequencing by hybridisation

Scanning: PTT*, SSCP, DGGE, TGGE, Cleavase, Heteroduplex analysis, CMC, Enzymatic mismatch cleavage

15 * Note: not useful for detection of promoter polymorphisms.

Hybridisation Based

Solid phase hybridisation: Dot blots, MASDA, Reverse dot blots, Oligonucleotide arrays (DNA Chips)

Solution phase hybridisation: Taqman™ - US-5210015 & US-5487972 (Hoffmann-La Roche), Molecular Beacons - Tyagi *et al* (1996), Nature Biotechnology, 14, 303; WO 5 95/13399 (Public Health Inst., New York)

Extension Based: ARMS™, ALEX™ - European Patent No. EP 332435 B1 (Zeneca Limited), COPS - Gibbs *et al* (1989), Nucleic Acids Research, 17, 2347.

Incorporation Based: Mini-sequencing, APEX

Restriction Enzyme Based: RFLP, Restriction site generating PCR

10 **Ligation Based:** OLA

Other: Invader assay

Table 2 - Signal Generation or Detection Systems

Fluorescence: FRET, Fluorescence quenching, Fluorescence polarisation - United Kingdom

15 Patent No. 2228998 (Zeneca Limited)

Other: Chemiluminescence, Electrochemiluminescence, Raman, Radioactivity, Colorimetric, Hybridisation protection assay, Mass spectrometry

Table 3 - Further Amplification Methods

20 SSR, NASBA, LCR, SDA, b-DNA

Table 4- Protein variation detection methods

Immunoassay

Immunohistology

Peptide sequencing

25 Immunoassay techniques are known in the art e.g. A Practical Guide to ELISA by D M Kemeny, Pergamon Press 1991; Principles and Practice of Immunoassay, 2nd edition, C P Price & D J Newman, 1997, published by Stockton Press in USA & Canada and by Macmillan Reference in the United Kingdom. Histological techniques are known in the art e.g. Theory and Practice of Histological Techniques, 4th Edition, edited by JD Bancroft and A

30 Stevens, Churchill Livingstone, 1996. Protein sequencing is described in Laboratory techniques Biochemistry and Molecular Biology, Volume 9, Sequencing of Proteins and Polypeptides, G Allen, 2nd revised edition, Elsevier, 1989.

Preferred mutation detection techniques include ARMS™, ALEX™, COPS, Taqman, Molecular Beacons, RFLP, restriction site based PCR and FRET techniques, polyacrylamide gel electrophoresis and capillary electrophoresis.

Particularly preferred methods include ARMS™ and RFLP based methods. ARMS™ 5 is an especially preferred method.

In a further aspect, the methods of the invention are used to assess the pharmacogenetics of a drug transportable by OATPF.

Assays, for example reporter-based assays, may be devised to detect whether one or more of the above polymorphisms affect transcription levels and/or message stability.

10 Individuals who carry particular allelic variants of the OATPF gene may therefore exhibit differences in their ability to regulate protein biosynthesis under different physiological conditions and will display altered abilities to react to different diseases. In addition, differences arising as a result of allelic variation may have a direct effect on the response of an individual to drug therapy. The methods of the invention may be useful both to 15 predict the clinical response to such agents and to determine therapeutic dose.

In a further aspect, the methods of the invention, are used to assess the predisposition and/or susceptibility of an individual to diseases mediated by OATPF. The present invention may be used to recognise individuals who are particularly at risk from developing such diseases.

20 In a further aspect, the methods of the invention are used in the development of new drug therapies which selectively target one or more allelic variants of the OATPF gene. Identification of a link between a particular allelic variant and predisposition to disease development or response to drug therapy may have a significant impact on the design of new drugs. Drugs may be designed to regulate the biological activity of variants implicated in the 25 disease process whilst minimising effects on other variants.

In a further aspect of the invention the presence or absence of variant nucleotides is detected by reference to the loss or gain of, optionally engineered, sites recognised by restriction enzymes.

According to another aspect of the present invention there is provided a human 30 OATPF gene or its complementary strand comprising a variant allelic polymorphism at one or more of positions defined herein or a fragment thereof of at least 20 bases comprising at least one novel polymorphism.

Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

According to another aspect of the present invention there is provided a polynucleotide comprising at least 20 contiguous bases of the human OATPF gene and comprising an allelic

5 variant selected from any of the following:

Region	variant	Position
Exon 1	G	86 (SEQ ID NO: 16)
Exon 4	T	505 (SEQ ID NO: 16)
Exon 9	G	1339 (SEQ ID NO: 16)
Exon 14	T	1991 (SEQ ID NO: 16)
Intronic	ACTTTGAAAG	11-16 (SEQ ID NO: 15)

According to another aspect of the present invention there is provided a human OATPF gene or its complementary strand comprising a polymorphism, preferably corresponding with one or more the positions defined herein or a fragment thereof of at least 10 20 bases comprising at least one polymorphism.

Fragments are at least 17 bases, more preferably at least 20 bases, more preferably at least 30 bases.

The invention further provides a nucleotide primer which can detect a polymorphism of the invention.

15 According to another aspect of the present invention there is provided an allele specific primer capable of detecting an OATPF gene polymorphism, preferably at one or more of the positions as defined herein.

An allele specific primer is used, generally together with a constant primer, in an amplification reaction such as a PCR reaction, which provides the discrimination between 20 alleles through selective amplification of one allele at a particular sequence position e.g. as used for ARMS™ assays. The allele specific primer is preferably 17- 50 nucleotides, more preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

An allele specific primer preferably corresponds exactly with the allele to be detected but derivatives thereof are also contemplated wherein about 6-8 of the nucleotides at the 3' 25 terminus correspond with the allele to be detected and wherein up to 10, such as up to 8, 6, 4, 2, or 1 of the remaining nucleotides may be varied without significantly affecting the properties of the primer.

Primers may be manufactured using any convenient method of synthesis. Examples of such methods may be found in standard textbooks, for example "Protocols for Oligonucleotides and Analogues; Synthesis and Properties," Methods in Molecular Biology Series; Volume 20; Ed. Sudhir Agrawal, Humana ISBN: 0-89603-247-7; 1st Edition. If 5 required the primer(s) may be labelled to facilitate detection.

According to another aspect of the present invention there is provided an allele-specific oligonucleotide probe capable of detecting an OATPF gene polymorphism, preferably at one or more of the positions defined herein.

The allele-specific oligonucleotide probe is preferably 17- 50 nucleotides, more 10 preferably about 17-35 nucleotides, more preferably about 17-30 nucleotides.

The design of such probes will be apparent to the molecular biologist of ordinary skill. Such probes are of any convenient length such as up to 50 bases, up to 40 bases, more conveniently up to 30 bases in length, such as for example 8-25 or 8-15 bases in length. In general such probes will comprise base sequences entirely complementary to the 15 corresponding wild type or variant locus in the gene. However, if required one or more mismatches may be introduced, provided that the discriminatory power of the oligonucleotide probe is not unduly affected. The probes of the invention may carry one or more labels to facilitate detection.

According to another aspect of the present invention there is provided an allele 20 specific primer or an allele specific oligonucleotide probe capable of detecting an OATPF gene polymorphism at one of the positions defined herein.

According to another aspect of the present invention there is provided a diagnostic kit comprising an allele specific oligonucleotide probe of the invention and/or an allele-specific primer of the invention.

25 The diagnostic kits may comprise appropriate packaging and instructions for use in the methods of the invention. Such kits may further comprise appropriate buffer(s) and polymerase(s) such as thermostable polymerases, for example taq polymerase.

In another aspect of the invention, the polymorphisms of this invention may be used as 30 genetic markers in linkage studies. This particularly applies to the polymorphisms of relatively high frequency. The OATPF gene is on chromosome 12. Low frequency polymorphisms may be particularly useful for haplotyping as described below. A haplotype is a set of alleles found at linked polymorphic sites (such as within a gene) on a single (paternal

or maternal) chromosome. If recombination within the gene is random, there may be as many as 2^n haplotypes, where 2 is the number of alleles at each SNP and n is the number of SNPs. One approach to identifying mutations or polymorphisms which are correlated with clinical response is to carry out an association study using all the haplotypes that can be identified in 5 the population of interest. The frequency of each haplotype is limited by the frequency of its rarest allele, so that polymorphisms with low frequency alleles are particularly useful as markers of low frequency haplotypes. As particular mutations or polymorphisms associated with certain clinical features, such as adverse or abnormal events, are likely to be of low frequency within the population, low frequency polymorphisms may be particularly useful in 10 identifying these mutations (for examples see: De Stefano V *et al.* *Ann Hum Genet* (1998) 62:481-90; and Keightley AM *et al.* *Blood* (1999) 93:4277-83).

According to another aspect of the present invention there is provided a computer readable medium comprising at least one novel sequence of the invention stored on the medium. The computer readable medium may be used, for example, in homology 15 searching, mapping, haplotyping, genotyping or pharmacogenetic analysis or any other bioinformatic analysis. The reader is referred to Bioinformatics, A practical guide to the analysis of genes and proteins, Edited by A D Baxevanis & B F F Ouellette, John Wiley & Sons, 1998. Any computer readable medium may be used, for example, compact disk, tape, floppy disk, hard drive or computer chips.

20 The polynucleotide sequences of the invention, or parts thereof, particularly those relating to and identifying the polymorphisms identified herein represent a valuable information source, for example, to characterise individuals in terms of haplotype and other sub-groupings, such as investigation of susceptibility to treatment with particular drugs. These approaches are most easily facilitated by storing the sequence information in a 25 computer readable medium and then using the information in standard bioinformatics programs or to search sequence databases using state of the art searching tools such as "GCC". Thus, the polynucleotide sequences of the invention are particularly useful as components in databases useful for sequence identity and other search analyses. As used herein, storage of the sequence information in a computer readable medium and use in 30 sequence databases in relation to 'polynucleotide or polynucleotide sequence of the invention' covers any detectable chemical or physical characteristic of a polynucleotide of the invention that may be reduced to, converted into or stored in a tangible medium, such as a computer

disk, preferably in a computer readable form. For example, chromatographic scan data or peak data, photographic scan or peak data, mass spectrographic data, sequence gel (or other) data.

The invention provides a computer readable medium having stored thereon one or 5 more polynucleotide sequences of the invention. For example, a computer readable medium is provided comprising and having stored thereon a member selected from the group consisting of: a polynucleotide comprising the sequence of a polynucleotide of the invention, a polynucleotide consisting of a polynucleotide of the invention, a polynucleotide which comprises part of a polynucleotide of the invention, which part includes at least one of the 10 polymorphisms of the invention, a set of polynucleotide sequences wherein the set includes at least one polynucleotide sequence of the invention, a data set comprising or consisting of a polynucleotide sequence of the invention or a part thereof comprising at least one of the polymorphisms identified herein.

A computer based method is also provided for performing sequence identification, 15 said method comprising the steps of providing a polynucleotide sequence comprising a polymorphism of the invention in a computer readable medium; and comparing said polymorphism containing polynucleotide sequence to at least one other polynucleotide or polypeptide sequence to identify identity (homology), i.e. screen for the presence of a polymorphism.

20 According to another aspect of the present invention there is provided a method of treating a human in need of treatment with a drug transportable by OATPF in which the method comprises:

- i) detection of a polymorphism in OATPF in a human, which method comprises determining the sequence of the human at one or more of: position 15-24 of SEQ ID NO: 15; 25 positions 86, 505, 1339 and 1991 of SEQ ID NO: 16; position 8 of SEQ ID NO: 17; and
- ii) administering an effective amount of the drug.

Preferably determination of the status of the human is clinically useful. Examples of clinical usefulness include deciding which statin drug or drugs to administer and/or in deciding on the effective amount of the statin drug or drugs. Statins already approved for use 30 in humans include atorvastatin, cerivastatin, fluvastatin, pravastatin and simvastatin. Statins under development include rosuvastatin. The reader is referred to the following references for further information: Drugs and Therapy Perspectives (12th May 1997), 9: 1-6; Chong (1997)

Pharmacotherapy 17: 1157-1177; Kellick (1997) Formulary 32: 352; Kathawala (1991) Medicinal Research Reviews, 11: 121-146; Jahng (1995) Drugs of the Future 20: 387-404, and Current Opinion in Lipidology, (1997), 8, 362 – 368; Olsson AG, Pears J, McKellar J, Mizan J & Raza A (2001) American Journal of Cardiology 88(5): 504-508. The term "drug

5 transportable by OATPF" means that transport by OATPF in humans is an important part of a drug exerting its pharmaceutical effect in man. For example, some statins have to be transported to the liver by OATPC, which is highly homologous to OATPF, to exert their lipid lowering effects. Accordingly, OATPF is expected to be involved in statin transport.

According to another aspect of the present invention there is provided use of a drug

10 transportable by OATPF in preparation of a medicament for treating a disease in a human determined as having a polymorphism defined herein.

According to another aspect of the present invention there is provided a pharmaceutical pack comprising OATPF transportable drug and instructions for administration of the drug to humans tested for a polymorphism described therein, preferably

15 at one or more of the positions defined herein.

One of the polymorphisms of the present invention result in variation in the amino acid sequence of the translated protein. Polymorphism at position 86 as defined in SEQ ID NO: 16 results in an amino acid change from asparagine to aspartic acid at corresponding position 8 of the translated protein (Asn8Asp) as defined in SEQ ID NO: 17.

20 Thus according to another aspect of the present invention there is provided an allelic variant of human OATPF polypeptide having an aspartic acid at position 8 of SEQ ID NO: 17 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 8 of SEQ ID NO: 17.

25 Fragments of OATPF polypeptide are at least 10 amino acids, more preferably at least 15 amino acids, more preferably at least 20 amino acids. The polypeptides of the invention do not encompass naturally occurring polypeptides as they occur in nature, for example, the polypeptide is at least partially purified from at least one component with which it occurs naturally. Preferably the polypeptide is at least 30% pure, more preferably at least 60% pure, more preferably at least 90% pure, more preferably at least 95% pure, and more preferably at

30 least 99% pure.

According to another aspect of the present invention there is provided an antibody specific for an allelic variant of human OATPF polypeptide having an aspartic acid at position

8 of SEQ ID NO: 17 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 8 of SEQ ID NO: 17.

Antibodies can be prepared using any suitable method. For example, purified polypeptide may be utilized to prepare specific antibodies. The term "antibodies" is meant to 5 include polyclonal antibodies, monoclonal antibodies, and the various types of antibody constructs such as for example $F(ab')_2$, Fab and single chain Fv. Antibodies are defined to be specifically binding if they bind the allelic variant of OATPF with a K_a of greater than or equal to about 10^7 M^{-1} . Affinity of binding can be determined using conventional techniques, for example those described by Scatchard et al., *Ann. N.Y. Acad. Sci.*, 51:660 (1949).

10 Polyclonal antibodies can be readily generated from a variety of sources, for example, horses, cows, goats, sheep, dogs, chickens, rabbits, mice or rats, using procedures that are well-known in the art. In general, antigen is administered to the host animal typically through parenteral injection. The immunogenicity of antigen may be enhanced through the use of an adjuvant, for example, Freund's complete or incomplete adjuvant. Following booster 15 immunizations, small samples of serum are collected and tested for reactivity to antigen.

Examples of various assays useful for such determination include those described in:

Antibodies: A Laboratory Manual, Harlow and Lane (eds.), Cold Spring Harbor Laboratory Press, 1988; as well as procedures such as countercurrent immuno-electrophoresis (CIEP), radioimmunoassay, radioimmunoprecipitation, enzyme-linked immuno-sorbent assays

20 (ELISA), dot blot assays, and sandwich assays, see U.S. Patent Nos. 4,376,110 and 4,486,530.

Monoclonal antibodies may be readily prepared using well-known procedures, see for example, the procedures described in U.S. Patent Nos. RE 32,011, 4,902,614, 4,543,439 and 4,411,993; *Monoclonal Antibodies, Hybridomas: A New Dimension in Biological Analyses*, Plenum Press, Kennett, McKearn, and Bechtol (eds.), (1980).

25 The monoclonal antibodies of the invention can be produced using alternative techniques, such as those described by Alting-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas", *Strategies in Molecular Biology* 3: 1-9 (1990) which is incorporated herein by reference. Similarly, binding partners can be constructed using recombinant DNA techniques to incorporate the variable regions of a gene that encodes 30 a specific binding antibody. Such a technique is described in Larrick et al., *Biotechnology*, 7: 394 (1989).

Once isolated and purified, the antibodies may be used to detect the presence of antigen in a sample using established assay protocols, see for example "A Practical Guide to ELISA" by D. M. Kemeny, Pergamon Press, Oxford, England.

According to another aspect of the invention there is provided a diagnostic kit
5 comprising an antibody of the invention.

The invention will now be illustrated but not limited by reference to the following Examples and Figure 1 is a schematic representation of the genomic DNA sequence upstream of Exon 1 of the OATPF gene, and shown relative to the corresponding nucleotide positions of SEQ ID NO: 15 and SEQ ID NO: 16. All temperatures are in degrees Celsius.

10 In the Examples below, unless otherwise stated, the following methodology and materials have been applied.

AMPLITAQ™, available from Perkin-Elmer Cetus, may be used as the source of thermostable DNA polymerase.

General molecular biology procedures can be followed from any of the methods
15 described in "Molecular Cloning - A Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989) or in "Current Protocols in Molecular Biology Volumes 1-3, edited by F M Asubel, R Brent and R E Kingston; published by John Wiley, 1998.

EXAMPLES

20 Example 1

Identification of Polymorphisms

1. Methods

The cDNA sequence of OATPF (AF260704) was used to identify the genomic position of the gene and obtain genomic DNA sequence. The genomic DNA sequence was
25 used to design PCR primers to amplify over the exons and intron/exon boundaries of the full length of the OATP gene. Twenty-nine individual Caucasian genomic DNA samples were used as templates for PCR amplification. The products were then sequenced by dye-primer sequencing using Amersham's MegaBACE™ technology. The alignment of sequence traces enabled the identification of polymorphisms. The frequency of the polymorphisms was
30 confirmed using genomic DNA from 20 individuals by primer extension analysis by DHPLC using the WAVE® system by Transgenomics and also by sequencing as described above. The deletion-insertion event was confirmed by sequencing in the forward and reverse direction.

PCR products

Polymorphism	PCR forward oligo	PCR reverse oligo	Primer used for confirmation of polymorphism
Exon 1	(SEQ ID NO: 1)	(SEQ ID NO: 2)	(SEQ ID NO: 3)
Exon 4	(SEQ ID NO: 4)	(SEQ ID NO: 5)	(SEQ ID NO: 6)
Exon 9	(SEQ ID NO: 7)	(SEQ ID NO: 8)	(SEQ ID NO: 9)
Exon 14	(SEQ ID NO: 10)	(SEQ ID NO: 11)	(SEQ ID NO: 12)
Intronic	(SEQ ID NO: 13)	(SEQ ID NO: 14)	N/a

PCR conditions:

5 18 μ l ABgene 2mM Reddy load including Taq polymerase
 1 μ l 5 μ M primer pair mix
 1 μ l genomic DNA (various individuals)

PCR programme:

10 94°C 1min; (94°C 30sec, 58°C 30sec, 72°C 2 min) for 34 cycles; 72°C 10 min.

2. OATPF Polymorphisms

15 Sequencing of DNA from 20 individuals identified the following 5 polymorphisms in the OATPF DNA sequence:

Position of SEQ ID NO 16	Region	Variation	Resultant codon change	Protein sequence SEQ ID NO 17	Frequency variant allele
86	Exon 1	A/G	aat-gat	Asn8Asp	0.03G
505	Exon 4	C/T	N/a	Ser147Ser	0.46T
1339	Exon 9	A/G	N/a	Ala425Ala	0.05G
1991	Exon 14	C/T	N/a	Leu643Leu	0.25T

Position of SEQ ID NO: 15	Region	Variation	Resultant codon change	Protein sequence SEQ ID NO 17	Frequency variant allele
11-16	Intronic	TAAAAA/ACTTGAAAG	N/a	N/a	0.06ACTTGAAAG

Claims

1. A method for the detection of a polymorphism in OATPF in a human which method comprises determining the sequence of the human at any one of the following positions:
 - 5 position 11-16 of SEQ ID NO: 15;
positions 86, 505, 1339 and 1991 of SEQ ID NO: 16;
position 8 of SEQ ID NO: 17.
 2. A method according to claim 1 wherein the polymorphism is further defined as:
polymorphism at position 11-16 is presence of TAAAAAA and/or insertion of ACTTTGAAAG
10 in lieu thereof;
polymorphism at position 86 is presence of A and/or G;
polymorphism at position 505 is presence of C and/or T;
polymorphism at position 1339 is presence of A and/or G;
polymorphism at position 1991 is presence of A and/or T; and
 - 15 polymorphism at position 8 is presence of Asn and/or Asp.
3. A method according to claim 1 or 2 wherein the method for detection of a nucleic acid polymorphism is selected from amplification refractory mutation system and restriction fragment length polymorphism.
4. Use of a method defined in any of claims 1-3 to assess the pharmacogenetics of a drug
20 transportable by OATPF.
5. A polynucleotide comprising at least 20 contiguous bases of the human OATPF gene and comprising an allelic variant selected from any of the following:

Region	variant	Position
Exon 1	G	86 (SEQ ID NO: 16)
Exon 4	T	505 (SEQ ID NO: 16)
Exon 9	G	1339 (SEQ ID NO: 16)
Exon 14	T	1991 (SEQ ID NO: 16)
Intronic	ACTTTGAAAG	11-20 (SEQ ID NO: 15)

6. An allele specific primer capable of detecting an OATPF gene polymorphism at
25 position 11-16 of SEQ ID NO: 15, and position 86, 505, 1339 and 1991 of SEQ ID NO: 16.
7. An allele specific oligonucleotide probe capable of detecting a OATPF gene polymorphism at position 11-16 of SEQ ID NO: 15 and position 86, 505, 1339 and 1991 of SEQ ID NO: 16.

8. A diagnostic kit comprising an allele specific oligonucleotide probe of claim 7 and/or an allele-specific primer of claim 6.
9. A method of treating a human in need of treatment with a drug transportable by OATPF in which the method comprises:
 - 5 i) detection of a polymorphism in OATPF in a human, which method comprises determining the sequence of the human at one or more of:
position 11-16 of SEQ ID NO: 15;
positions 86, 505, 1339 and 1991 of SEQ ID NO: 16;
position 8 of SEQ ID NO: 17; and
 - 10 ii) administering an effective amount of the drug.
10. Use of a drug transportable by OATPF in preparation of a medicament for treating a disease in a human determined as having a polymorphism at one of the following positions:
position 11-16 of SEQ ID NO: 15;
positions 86, 505, 1339 and 1991 of SEQ ID NO: 16;
- 15 position 8 of SEQ ID NO: 17.
11. An allelic variant of human OATPF polypeptide comprising an aspartic acid at position 8 of SEQ ID NO: 17 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 8 of SEQ ID NO: 17.
12. An antibody specific for an allelic variant of human OATPF polypeptide as described
20 herein having an aspartic acid at position 8 of SEQ ID NO: 17 or a fragment thereof comprising at least 10 amino acids provided that the fragment comprises the allelic variant at position 8 of SEQ ID NO: 17.
13. A diagnostic kit comprising an antibody of claim 12.

-1-

SEQUENCE LISTING

<110> ASTRAZENECA AB

5 <120> METHODS

<130> JHU/100692-1 GB 09APR02

<140>

10 <141>

<160> 17

<170> PatentIn Ver. 2.1

15

<210> 1

<211> 40

<212> DNA

<213> Artificial Sequence

20

<400> 1

actgtaaaac gacggccagt aatgaggctt aaactggca

40

25 <210> 2

<211> 40

<212> DNA

<213> Artificial Sequence

30 <220>

<223> Description of Artificial Sequence:PCR reverse
primer OATPF-1R

<400> 2

35 accaggaaac agctatgacc ggttagagatt gcttgcacccg

40

<210> 3

<211> 20

40 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Validation

45 primer

<400> 3
tggacacttc atccaaagaa 20

5
<210> 4
<211> 41
<212> DNA
<213> Artificial Sequence

10
<220>
<223> Description of Artificial Sequence:PCR forward
primer OATPF-2F

15 <400> 4
actgtaaaac gacggccagt ctatgagcca gatcttctgg c 41

20 <210> 5
<211> 43
<212> DNA
<213> Artificial Sequence

25 <220>
<223> Description of Artificial Sequence:PCR reverse
primer OATPF-2R

<400> 5
accaggaaac agctatgacc cagaagcttt gaaagatttt ccc 43

30
<210> 6
<211> 20
<212> DNA

35 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:Validation
primer

40
<400> 6
tattctcattt cctccaaattc 20

45 <210> 7

<211> 40
<212> DNA
<213> Artificial Sequence

5 <220>
<223> Description of Artificial Sequence:PCR forward
primer OATPF-3F

<400> 7

10 actgtaaaac gacggccagt tgggcaccta attgctacct 40

<210> 8
<211> 40

15 <212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR reverse

20 primer OATPF-3R

<400> 8

accagggaaac agctatgacc tgagggaaaca tacccttggt 40

25

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

30

<220>
<223> Description of Artificial Sequence:Validation
primer

35 <400> 9

atcagtgtgt gtggagctgc 20

<210> 10

40 <211> 40
<212> DNA
<213> Artificial Sequence

<220>

45 <223> Description of Artificial Sequence:PCR forward

primer OATPF-4F

<400> 10
actgtaaaac gacggccagt gctgttctag gcaaacaggg 40

5

<210> 11

<211> 16

<212> DNA

10 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR reverse
primer OATPF-4R

15

<400> 11

ccagtagttg ggtttgt 16

20 <210> 12

<211> 20

<212> DNA

<213> Artificial Sequence

25 <220>

<223> Description of Artificial Sequence:Validation
primer

<400> 12

30 cttcttctag acatataatat 20

<210> 13

<211> 40

35 <212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR forward

40 primer OATPF-5F

<400> 13

actgtaaaac gacggccagt cttcagctct ttctgtgccc

40

45

<210> 14
<211> 41
<212> DNA
<213> Artificial Sequence

5

<220>
<223> Description of Artificial Sequence:PCR reverse
primer OATPF-5R

10 <400> 14

accagggaaac agctatgacc ttccatcaaa ctaatgaggg g

41

<210> 15

15 <211> 54

<212> DNA

<213> Homo sapiens

<400> 15

20 atttttactt taaaaactaa ctttgacaga tcagagtcaa ggaatgtgtt tata

54

<210> 16

<211> 3077

25 <212> DNA

<213> Homo sapiens

<400> 16

cattgaaagg aatggctat ctttgatctc ttcctccaga tcagagtcaa ggaatgtgtt 60

30 tataatggac acttcatcca aagaaaatat ccagttgttc tgcaaaaactt cagtgcacc 120

tgttggaaagg ctttctttta aaacagaata tccctcctca gaagaaaagc aaccatgctg 180

tggtaacta aagggtttct tttgtgcctt gtctttgtt tactttgcca aagcatggc 240

agaaggctat ctgaagagca ccatcactca gatagagaga aggtttgata tcccttc 300

actgggtggga gttattgtat gtagtttga aattggaaat ctcttagtta taacatttgt 360

35 tagctacttt ggagccaaac ttcacaggcc aaaaataatt ggaggcagggt gtgtatcat 420

gggagttgga acactgctca ttgcaatgcc tcagttcttc atggaggcagt acaaataatga 480

gagatattct ctttcttcca attccactct cagcatctc ccgtgtctcc tagagtcaag 540

cagtcaatta ccagtttcag ttatggaaaa atcaaaatcc aaaataagta acgaatgtga 600

agtggacact agcttttcca ttttttttgc ggcaatcttc ttcgttggaaat 660

40 aggagaaaact cccatttcagc ctttgggcat tgcctacctg gatgattttg ccagtgaaga 720

caatgcagct ttctatattt ggtgtgtgc aacgggttgc attataggac caatcttgg 780

tttccctgtta ggctcattat gtgcctaaact atatgttgc attggctttg taaacctaga 840

tcacataacc attaccccaa aagatccccaa gtgggttagga gcctgggtggc ttggctatct 900

aatagcagga atcataagtc ttcttgcagc ttttttttttgc ttttttttgc ttttttttgc 960

45 accaagatcc caaagtagag aggattctaa ttcttcttcc gagaatccca agtttattat 1020

<210> 17

<211> 712

40 <212> PRT

<213> *Homo sapiens*

<400> 17

Met Asp Thr Ser Ser Lys Glu Asn Ile Gln Leu Phe Cys Lys Thr Ser

Val Gln Pro Val Gly Arg Pro Ser Phe Lys Thr Glu Tyr Pro Ser Ser
20 25 30

5 Glu Glu Lys Gln Pro Cys Cys Gly Glu Leu Lys Val Phe Leu Cys Ala
35 40 45

Leu Ser Phe Val Tyr Phe Ala Lys Ala Leu Ala Glu Gly Tyr Leu Lys
50 55 60

10 Ser Thr Ile Thr Gln Ile Glu Arg Arg Phe Asp Ile Pro Ser Ser Leu
65 70 75 80

Val Gly Val Ile Asp Gly Ser Phe Glu Ile Gly Asn Leu Leu Val Ile
15 85 90 95

Thr Phe Val Ser Tyr Phe Gly Ala Lys Leu His Arg Pro Lys Ile Ile
100 105 110

20 Gly Ala Gly Cys Val Ile Met Gly Val Gly Thr Leu Leu Ile Ala Met
115 120 125

Pro Gln Phe Phe Met Glu Gln Tyr Lys Tyr Glu Arg Tyr Ser Pro Ser
130 135 140

25 Ser Asn Ser Thr Leu Ser Ile Ser Pro Cys Leu Leu Glu Ser Ser Ser
145 150 155 160

Gln Leu Pro Val Ser Val Met Glu Lys Ser Lys Ser Lys Ile Ser Asn
30 165 170 175

Glu Cys Glu Val Asp Thr Ser Ser Met Trp Ile Tyr Val Phe Leu
180 185 190

35 Gly Asn Leu Leu Arg Gly Ile Gly Glu Thr Pro Ile Gln Pro Leu Gly
195 200 205

Ile Ala Tyr Leu Asp Asp Phe Ala Ser Glu Asp Asn Ala Ala Phe Tyr
210 215 220

40 Ile Gly Cys Val Gln Thr Val Ala Ile Ile Gly Pro Ile Phe Gly Phe
225 230 235 240

Leu Leu Gly Ser Leu Cys Ala Lys Leu Tyr Val Asp Ile Gly Phe Val
45 245 250 255

Asn Leu Asp His Ile Thr Ile Thr Pro Lys Asp Pro Gln Trp Val Gly
260 265 270

5 Ala Trp Trp Leu Gly Tyr Leu Ile Ala Gly Ile Ile Ser Leu Leu Ala
275 280 285

Ala Val Pro Phe Trp Tyr Leu Pro Lys Ser Leu Pro Arg Ser Gln Ser
290 295 300

10 Arg Glu Asp Ser Asn Ser Ser Ser Glu Lys Ser Lys Phe Ile Ile Asp
305 310 315 320

Asp His Thr Asp Tyr Gln Thr Pro Gln Gly Glu Asn Ala Lys Ile Met
15 325 330 335

Glu Met Ala Arg Asp Phe Leu Pro Ser Leu Lys Asn Leu Phe Gly Asn
340 345 350

20 Pro Val Tyr Phe Leu Tyr Leu Cys Thr Ser Thr Val Gln Phe Asn Ser
355 360 365

Leu Phe Gly Met Val Thr Tyr Lys Pro Lys Tyr Ile Glu Gln Gln Tyr
370 375 380

25 Gly Gln Ser Ser Ser Arg Ala Asn Phe Val Ile Gly Leu Ile Asn Ile
385 390 395 400

Pro Ala Val Ala Leu Gly Ile Phe Ser Gly Gly Ile Val Met Lys Lys
30 405 410 415

Phe Arg Ile Ser Val Cys Gly Ala Ala Lys Leu Tyr Leu Gly Ser Ser
420 425 430

35 Val Phe Gly Tyr Leu Leu Phe Leu Ser Leu Phe Ala Leu Gly Cys Glu
435 440 445

Asn Ser Asp Val Ala Gly Leu Thr Val Ser Tyr Gln Gly Thr Lys Pro
450 455 460

40 Val Ser Tyr His Glu Arg Ala Leu Phe Ser Asp Cys Asn Ser Arg Cys
465 470 475 480

Lys Cys Ser Glu Thr Lys Trp Glu Pro Met Cys Gly Glu Asn Gly Ile
45 485 490 495

Thr Tyr Val Ser Ala Cys Leu Ala Gly Cys Gln Thr Ser Asn Arg Ser
500 505 510

5 Gly Lys Asn Ile Ile Phe Tyr Asn Cys Thr Cys Val Gly Ile Ala Ala
515 520 525

Ser Lys Ser Gly Asn Ser Ser Gly Ile Val Gly Arg Cys Gln Lys Asp
530 535 540

10 Asn Gly Cys Pro Gln Met Phe Leu Tyr Phe Leu Val Ile Ser Val Ile
545 550 555 560

Thr Ser Tyr Thr Leu Ser Leu Gly Gly Ile Pro Gly Tyr Ile Leu Leu
15 565 570 575

Leu Arg Cys Ile Lys Pro Gln Leu Lys Ser Phe Ala Leu Gly Ile Tyr
580 585 590

20 Thr Leu Ala Ile Arg Val Leu Ala Gly Ile Pro Ala Pro Val Tyr Phe
595 600 605

Gly Val Leu Ile Asp Thr Ser Cys Leu Lys Trp Gly Phe Lys Arg Cys
610 615 620

25 Gly Ser Arg Gly Ser Cys Arg Leu Tyr Asp Ser Asn Val Phe Arg His
625 630 635 640


Ile Tyr Leu Gly Leu Thr Val Ile Leu Gly Thr Val Ser Ile Leu Leu
30 645 650 655

Ser Ile Ala Val Leu Phe Ile Leu Lys Lys Asn Tyr Val Ser Lys His
660 665 670

35 Arg Ser Phe Ile Thr Lys Arg Glu Arg Thr Met Val Ser Thr Arg Phe
675 680 685

Gln Lys Glu Asn Tyr Thr Ser Asp His Leu Leu Gln Pro Asn Tyr
690 695 700

40 Trp Pro Gly Lys Glu Thr Gln Leu
705 710

Figure 1

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT OR DRAWING
- BLURED OR ILLEGIBLE TEXT OR DRAWING
- SKEWED/SLANTED IMAGES
- COLORED OR BLACK AND WHITE PHOTOGRAPHS
- GRAY SCALE DOCUMENTS
- LINES OR MARKS ON ORIGINAL DOCUMENT
- REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox